Iovance Biotherapeutics (NASDAQ: IOVA) reported Q2 EPS of ($0.47), $0.03 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $240 thousand versus the consensus estimate of $3.91 million.

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.